Follow GoodRx to never miss an important update.
The company is expected to report revenue of about 200 million dollars and earnings of roughly 8 cents per share. This report will be a key check on the company's shift toward its Pharma Direct business, which lets drug makers offer coupons directly to patients through the platform. While the older consumer discount business has faced pressure from pharmacy closures, this newer segment has been the main reason for recent growth.
A closely watched index of consumer sentiment fell to its lowest level since May. While the reading was slightly better than some economists expected, it shows that Americans are feeling the pinch of higher costs. For a company like GoodRx, which helps people find cheaper prescriptions, a tighter consumer budget can be a double-edged sword: it may drive more people to look for discounts, but it also reflects a general pull-back in spending.
Source: Bloomberg Markets and Finance
Rising healthcare costs and shrinking insurance options are pushing more Americans toward subscription-based drug plans. These services charge a monthly fee for access to low-cost medications, bypassing the traditional insurance model.
This trend supports the company's move to work more closely with drug makers. As more people look for ways to pay for medicine outside of standard work-provided insurance, the platform's role as a direct link between patients and manufacturers becomes more valuable.
Source: Reuters
Management has become very good at hitting their targets exactly. After a string of small misses, they have spent the last year delivering results that land right on the money.
| Expectation | |
|---|---|
| EPS | $0.08 |
| Revenue | $202M |